

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

POSITIVE PROFIT ALERT

This announcement is made by Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2023 and the information currently available to the Board, the Group expects to record profit attributable to Shareholders with a range from approximately RMB10 million to RMB25 million for the six months ended 30 June 2023, as compared with the loss attributable to Shareholders of approximately RMB7.0 million for the six months ended 30 June 2022. The turnaround from loss to profit of the Group was mainly attributable to the increase in revenue for the six months ended 30 June 2023 by not less than 90% as compared to that for the six months ended 30 June 2022. The increase in revenue is due to the combined effects of (1) with the ease of the COVID-19 pandemic and the recovering market environment, an increase in market demand; and (2) the Group’s efforts of expanding sales network and strengthening product branding.

The Company is still in the process of finalising the consolidated interim results of the Group for the six months ended 30 June 2023. The information contained in this announcement only represents a preliminary assessment based on the unaudited management accounts for the six months ended 30 June 2023 and the information currently available to the Board which has not been reviewed or audited by the auditors of the Company. Shareholders and potential investors are advised to read carefully the interim results announcement of the Group for the six months ended 30 June 2023 which is expected to be published before the end of August 2023.

* *For identification purposes only*

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Changcheng
Chairman and Executive Director

Hong Kong, 10 August 2023

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming as executive Directors and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.